BioStem Technologies has launched its Amnion Division, BioStem Life Sciences, to develop and market regenerative and therapeutic biologics utilizing human placental tissue allografts for multiple sectors of healthcare. 

The established management team has an extensive background of successfully developing, processing, and selling minimally-manipulated Amniotic Tissue products within the U.S., including the likes of amniotic and chorion products, flowable allografts’, and wound care products. This divisional launch will serve as a platform for developing additional amniotic tissue-based products, accelerating year-over-year growth and revenue for BioStem Technologies.

BioStem Technologies will also be leveraging its assets within the pharmaceutical manufacturing industry to ensure all products will be processed to the American Association of Tissue Banks’ (AATB) standards and that the facility will be operated under GTP and Manufacturing guidelines.

Henry (Chip) Van Vurst said; “We are very excited about the launch of this new division and the revenue possibilities it represents to BioStem Technologies. We are entirely committed to creating and manufacturing Amniotic products using pharmaceutical manufacturing standards which we feel will set us apart from the rest of the industry in quality, safety and efficacy.”